8-KLeadership ChangesExhibits & Filings

Elevance Health, Inc. 8-K Report, Executive Changes (Aug 4, 2021)

Filed August 4, 2021For Securities:ELV

Summary

Elevance Health, Inc. (ELV) announced a key addition to its Board of Directors. Susan Dodson DeVore has been elected as an independent director, effective immediately, with her term set to expire at the 2022 annual meeting of shareholders. This appointment is significant as it brings an experienced individual with expertise in financial oversight to the company's governance structure. Ms. DeVore's appointment includes her placement on the Audit and Finance Committees, underscoring her financial acumen. The company has confirmed she meets the qualifications of an "audit committee financial expert." Investors should note that Ms. DeVore's compensation will follow the standard program for non-employee directors. This move suggests a continued focus on robust financial governance and strategic oversight at the board level.

Key Highlights

  • 1Susan Dodson DeVore elected as an independent director to the Board.
  • 2Director term to expire at the 2022 annual meeting of shareholders.
  • 3Ms. DeVore appointed to the Audit and Finance Committees.
  • 4Ms. DeVore qualifies as an "audit committee financial expert."
  • 5No undisclosed arrangements or material interests regarding Ms. DeVore's election.
  • 6Compensation for Ms. DeVore will align with the standard non-employee director compensation program.

Frequently Asked Questions

Susan Dodson DeVore has been elected as an independent director to Elevance Health's Board. Her appointment is likely intended to strengthen the board's expertise, particularly in financial matters, given her qualifications as an "audit committee financial expert" and her placement on the Audit and Finance Committees.

Ms. DeVore's appointment, especially to the Audit and Finance Committees and her designation as an "audit committee financial expert," suggests a reinforcement of the company's financial governance and oversight. This can provide investors with increased confidence in the board's ability to manage financial reporting and risk.

No, Ms. DeVore will receive compensation in accordance with Elevance Health's standard compensation program for non-employee directors. Details of this program are available in their Form 10-Q for the quarter ended June 30, 2019.

The filing explicitly states that there are no arrangements or understandings that led to her election, nor does Ms. DeVore have any direct or indirect material interest in any transaction requiring disclosure under Item 404(a) of Regulation S-K. This indicates no apparent conflicts of interest at the time of her appointment.